886 related articles for article (PubMed ID: 24635642)
21. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of maraviroc.
Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
[TBL] [Abstract][Full Text] [Related]
23. Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists.
Poveda E; Alcamí J; Paredes R; Córdoba J; Gutiérrez F; Llibre JM; Delgado R; Pulido F; Iribarren JA; García Deltoro M; Hernández Quero J; Moreno S; García F
AIDS Rev; 2010; 12(3):135-48. PubMed ID: 20842202
[TBL] [Abstract][Full Text] [Related]
24. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
25. [Mechanisms of resistance and failure of treatment with maraviroc].
Delgado R
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():28-33. PubMed ID: 19133219
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
[TBL] [Abstract][Full Text] [Related]
27. Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.
Maeda Y; Takemura T; Chikata T; Kuwata T; Terasawa H; Fujimoto R; Kuse N; Akahoshi T; Murakoshi H; Tran GV; Zhang Y; Pham CH; Pham AHQ; Monde K; Sawa T; Matsushita S; Nguyen TV; Nguyen KV; Hasebe F; Yamashiro T; Takiguchi M
J Virol; 2020 Jun; 94(12):. PubMed ID: 32295903
[TBL] [Abstract][Full Text] [Related]
28. Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods.
Kalu AW; Telele NF; Aralaguppe SG; Gebre-Selassie S; Fekade D; Marrone G; Sonnerborg A
Curr HIV Res; 2018; 16(2):113-120. PubMed ID: 29766813
[TBL] [Abstract][Full Text] [Related]
29. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure.
Ferrer P; Tello M; Montecinos L; Tordecilla R; Rodríguez C; Beltrán C; Guzmán MA; Ferrés M; Pérez CM; Afani A
J Clin Virol; 2014 Jul; 60(3):290-4. PubMed ID: 24793966
[TBL] [Abstract][Full Text] [Related]
31. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
[TBL] [Abstract][Full Text] [Related]
32. HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients.
Visseaux B; Charpentier C; Rouard C; Fagard C; Glohi D; Tubiana R; Damond F; Brun-Vézinet F; Matheron S; Descamps D;
AIDS; 2014 Sep; 28(14):2160-2. PubMed ID: 25265081
[TBL] [Abstract][Full Text] [Related]
33. Genotypic coreceptor analysis.
Sierra S; Kaiser R; Thielen A; Lengauer T
Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
[TBL] [Abstract][Full Text] [Related]
34. Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.
Cavarelli M; Mainetti L; Pignataro AR; Bigoloni A; Tolazzi M; Galli A; Nozza S; Castagna A; Sampaolo M; Boeri E; Scarlatti G
AIDS Res Hum Retroviruses; 2014 Dec; 30(12):1243-50. PubMed ID: 25275490
[TBL] [Abstract][Full Text] [Related]
35. Profile of HIV type 1 coreceptor tropism among Kenyan patients from 2009 to 2010.
Nyamache AK; Muigai AW; Ng'ang'a Z; Khamadi SA
AIDS Res Hum Retroviruses; 2013 Aug; 29(8):1105-9. PubMed ID: 23617327
[TBL] [Abstract][Full Text] [Related]
36. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients.
Kagan RM; Johnson EP; Siaw M; Biswas P; Chapman DS; Su Z; Platt JL; Pesano RL
PLoS One; 2012; 7(9):e46334. PubMed ID: 23029482
[TBL] [Abstract][Full Text] [Related]
37. Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion.
Mulampaka SN; Dixit NM
PLoS One; 2011; 6(5):e19941. PubMed ID: 21647388
[TBL] [Abstract][Full Text] [Related]
38. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.
Treviño A; Soriano V; Poveda E; Parra P; Cabezas T; Caballero E; Roc L; Rodríguez C; Eiros JM; Lopez M; De Mendoza C;
J Antimicrob Chemother; 2014 Aug; 69(8):2191-4. PubMed ID: 24788659
[TBL] [Abstract][Full Text] [Related]
39. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.
Lin G; Bertolotti-Ciarlet A; Haggarty B; Romano J; Nolan KM; Leslie GJ; Jordan AP; Huang CC; Kwong PD; Doms RW; Hoxie JA
J Virol; 2007 Sep; 81(18):9956-66. PubMed ID: 17609282
[TBL] [Abstract][Full Text] [Related]
40. Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.
Cashin K; Jakobsen MR; Sterjovski J; Roche M; Ellett A; Flynn JK; Borm K; Gouillou M; Churchill MJ; Gorry PR
Retrovirology; 2013 Sep; 10():98. PubMed ID: 24041034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]